The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pathologic down-staging following standard (SD) MVAC (methotrexate-vinblastine-doxorubicine-cisplatin) or dose-dense MVAC (DD) neoadjuvant chemotherapy (NC) for muscle-invasive urothelial bladder cancer (UC): A retrospective multicenter cohort of the French Genitourinary Tumor Group (GETUG/AFU).
Damien Pouessel
No relevant relationships to disclose
Sylvie Chevret
No relevant relationships to disclose
Emmanuelle Bompas
No relevant relationships to disclose
Laurys Boudin
No relevant relationships to disclose
Charlotte Joly
No relevant relationships to disclose
Thomas Grellety
No relevant relationships to disclose
Safae Aarab Terrisse
No relevant relationships to disclose
Helen Jane Boyle
No relevant relationships to disclose
Guilhem Roubaud
No relevant relationships to disclose
Christine Chevreau
No relevant relationships to disclose
Jérôme Dauba
No relevant relationships to disclose
Guillaume Moriceau
No relevant relationships to disclose
Ingrid Alexandre
No relevant relationships to disclose
Gael Deplanque
No relevant relationships to disclose
Angelique Chapelle
No relevant relationships to disclose
Elodie Vauleon
No relevant relationships to disclose
Alexandre Colau
No relevant relationships to disclose
Francois Audenet
No relevant relationships to disclose
Stephane Culine
No relevant relationships to disclose